3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN

"Subjects will receive the iC9-GD2 T cells through an IV over 5 to 10 minutes.~Subjects will receive one of the following dose levels (cells/m2):~* Dose Level 1 = 1 x 10\^7~* Dose Level 2 = 1 x 10\^8~* Dose Level 3 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."

"For subjects who will receive a fresh T cell product:~* Dose Level 1 = 1 x 10\^8~* Dose Level 2 = 1.5 x 10\^8~* Dose Level 3 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."

Cyclophosphamide (500 mg/m2/day x 2 days, for patients \<12 kg = 16.7 mg/kg/day x 2 days)

Fludarabine (30 mg/m2/day x 3 days, for patients \<12 kg = 1 mg/kg/day x 3 days)

Pembrolizumab (2 mg/kg on Day -1 and on Day 21).

"For subjects who will receive a fresh T cell product:~* Dose Level 1 = 1.5 x 10\^8~* Dose Level 2 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."